Catalent buys Paragon in hot gene medicine market
The US’s Catalent will buy Paragon Bioservices in a debt and equity financed $1.2bn deal, as consolidation in the gene therapy market builds pace.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts